Payment overview · 2025
General Payments
$835.80
45 reported records · 6 companies
Healthcare provider profile · identity verified
Catherine M Thomas, M.D.
Allopathic & Osteopathic Physicians|General Practice · HATTIESBURG, MS · NPI 1093796500
Verified facts
What the public records show
CMS Open Payments records show Catherine M Thomas, M.D. received $835.80 in general payments during 2025 across 45 reported records.
Gilead Sciences, Inc. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Isentress by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $316.75 | 37.9% | 18 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $264.21 | 31.6% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $137.71 | 16.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.57 | 8.1% | 4 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $30.08 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.48 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $835.80 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $219.21 | 12 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $137.71 | 7 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $46.52 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.18 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.18 | 2 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $30.08 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $30.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 319 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 183 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
319 | 34 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
183 | 35 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 67 |
| Gabapentin | Gabapentin | 358 | 56 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 319 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 65 |
| Omeprazole | Omeprazole | 279 | 55 |
| Potassium Chloride | Potassium Chloride | 206 | 40 |
| Jardiance | Empagliflozin | 183 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 26 |
| Carvedilol | Carvedilol | 125 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 32 |
| Furosemide | Furosemide | 115 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 25 |
| Lisinopril | Lisinopril | 107 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 18 |
| Metformin Hcl | Metformin Hcl | 102 | 25 |
| Losartan Potassium | Losartan Potassium | 101 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 17 |
| Ezetimibe | Ezetimibe | 93 | 22 |
| Trazodone Hcl | Trazodone Hcl | 89 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 19 |
| Tivicay | Dolutegravir Sodium | 75 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 21 |
| Buspirone Hcl | Buspirone Hcl | 73 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 73 | suppressed |
| Ozempic | Semaglutide | 68 | 14 |
| Tramadol Hcl | Tramadol Hcl | 68 | 13 |
| Dovato | Dolutegravir Sodium/Lamivudine | 66 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 11 |
| Prezcobix | Darunavir/Cobicistat | 60 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 58 | suppressed |
| Ritonavir | Ritonavir | 56 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 12 |
| Glimepiride | Glimepiride | 51 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 13 |
| Descovy | Emtricitabine/Tenofov Alafenam | 46 | suppressed |
| Linzess | Linaclotide | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 14 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 44 | 11 |
| Eliquis | Apixaban | 44 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 44 | suppressed |
| Fluconazole | Fluconazole | 43 | 16 |
| Promethazine Hcl | Promethazine Hcl | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 41 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Darunavir | Darunavir | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 24 |
| Clotrimazole | Clotrimazole | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | suppressed |
| Isentress | Raltegravir Potassium | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Lamivudine | Lamivudine | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Etravirine | Etravirine | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Prezista | Darunavir | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 11 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $835.80 · 45 records | Gilead Sciences, Inc. | APRETUDE, Biktarvy, CABENUVA, CAPVAXIVE, DELSTRIGO, DOVATO, EGRIFTA, JARDIANCE, MAVYRET, MOUNJARO, PIFELTRO, TROGARZO, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error